Results 131 to 140 of about 1,397,668 (331)

Opportunities for improving the efficiency of paediatric HIV treatment programmes [PDF]

, 2015
Objectives: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on
Bakeera-Kitaka, S, Bwakura-Dangarembizi, M, Gibb, DM, Kekitinwa, A, Mabugu, T, Mugyenyi, P, Munderi, P, Musiime, V, Nahirya-Ntege, P, Nathoo, KJ, Revill, PA, Sculpher, MJ, Walker, AS, Walker, S   +13 more
core   +1 more source

Pioglitazone plus (−)‐epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells

FEBS Open Bio, EarlyView.
Aged human bmMSCs are seeded in the scaffold. Osteoblastic induction can slightly increase cell's bone‐forming activity to produce bone‐like tissues, shown as the sporadic xylenol orange‐stained spots (the lower left image). Notably, pioglitazone plus EGCG co‐treatment dramatically increases cell's bone‐forming activity and bone‐like tissue production (
Ching‐Yun Chen, Jia‐Ci Jhang, Chun‐Yi Peng, Quốc Cường Nguyễn, Feng‐Huei Lin, Hung‐Ming Wu, Shankung Lin   +6 more
wiley   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Alternatives to the quality-adjusted life year: How well do they address common criticisms? [PDF]

Health Serv Res, 2023
Rand LZ, Melendez-Torres GJ, Kesselheim AS.   +2 more
europepmc   +1 more source

Quality-Adjusted Life-Years Gain and Health Status in Patients with OSAS after One Year of Continuous Positive Airway Pressure Use [PDF]

, 2014
Camila F. Rizzi, Marcos Bosi Ferraz, Dalva Poyares, Sérgio Tufik   +3 more
openalex   +1 more source

Enhancing Oncological Care for India's Aging Population: Addressing the Complex Needs of Older Adults With Cancer

Aging and Cancer, EarlyView.
Aging‐associated physiological and molecular alterations pose significant challenges in cancer management among India's elderly. Limited geriatric oncology expertise, financial constraints, and inadequate specialized care exacerbate disparities. Strategic expansion of insurance coverage, integration of palliative care, and infrastructural advancements ...
Nihanthy D. Sreenath, Mathigatta Shivarudraiah S, Rajath Govind, Kaushik M R   +3 more
wiley   +1 more source

Estimates of Quality-Adjusted Life-Year Loss for Injuries in the United States. [PDF]

Med Decis Making, 2023
Raich W, Baxter J, Sheahan M, Goldhaber-Fiebert J, Sullivan P, Hanmer J.   +5 more
europepmc   +1 more source

Live Long, Live Well: Quantifying the Health of Heterogenous Populations [PDF]

Various health-, quality-, and disability-adjusted life year or life expectancy (HALY, QALY, DALY; HALE, QALE, DALE) measures have become gold standards for defining outcomes in technology evaluation, population health monitoring, and other evaluative ...
John Mullahy
core  

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source